Table 5. Association between clinical and confirmed peripheral and optical neuropathy and patient characteristics among 57 patients with multidrug-resistant tuberculosis, Pitié-Salpêtrière Hospital, Paris, France, 2011–2016*.

Characteristic	Clinical neuropathy			Confirmed neuropathy
	Value	p value*		Value	p value*
Age, OR (95% CI)†	1.83 (0.9–3.7)	0.09		1.66 (0.8–3.3)	0.14
Immunosuppression treatment, OR (95% CI)	0.91 (0.3–2.7)	0.98		2.1 (0.7–6.2)	0.18
History of intravenous drug use, OR (95% CI)	0.43 (0.5–4.9)	0.43		1.79 (0.6–5.4)	0.30
Opioid substitution therapy, OR (95% CI)	1.6 (0.4–6.1)	0.49		1.92 (0.5–7)	0.32
Albumin, g/L	0.81 (0.4–1.8)	0.61		1.01 (0.5–2.2)	0.98
Linezolid treatment duration, mo	0.47 (0.2–1.2)	0.10		1.11 (0.5–2.7)	0.82
Culture conversion, d	0.93 (0.8–1.1)	0.35		1.15 (0.9–1.4)	0.21
Trough linezolid concentration >2 mg/L	2.07 (0.6–7.3)	0.26		0.83 (0.3–2.7)	0.76

*p values from univariate logistic models. OR, odds ratio.
†Risk based on age increase by 10-y intervals.